Reviews:
Micrornas in prostate cancer: an overview
Metrics: PDF 2862 views | HTML 5569 views | ?
Abstract
Daniela Vanacore1,2,*, Mariarosaria Boccellino2,*, Sabrina Rossetti1,3, Carla Cavaliere1,4, Carmine D’Aniello1,5, Rossella Di Franco1,6, Francesco Jacopo Romano1, Micaela Montanari1,7, Elvira La Mantia1,8, Raffaele Piscitelli1,9, Flavia Nocerino1,10, Francesca Cappuccio1,11, Giovanni Grimaldi1,12, Alessandro Izzo1,12, Luigi Castaldo1,12, Maria Filomena Pepe1,8, Maria Gabriella Malzone1,8, Gelsomina Iovane3, Gianluca Ametrano1,6, Paola Stiuso2, Lucio Quagliuolo2, Daniela Barberio1,11, Sisto Perdonà12, Paolo Muto6, Maurizio Montella10, Piera Maiolino9, Bianca Maria Veneziani7, Gerardo Botti8,13, Michele Caraglia2 and Gaetano Facchini1,3
1Progetto ONCONET2.0, Linea progettuale 14 per l’implementazione della Prevenzione e Diagnosi Precoce del Tumore alla Prostata e Testicolo, Regione Campania, Italy
2Department of Biochemistry, Biophysics and General Pathology, University of Campania “L. Vanvitelli” Naples, Naples, Italy
3Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori ‘Fondazione G. Pascale’, IRCCS, Naples, Italy
4Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto, Taranto, Italy
5Division of Medical Oncology, A.O.R.N. dei COLLI “Ospedali Monaldi-Cotugno-CTO”, Napoli, Italy
6Radiation Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’, IRCCS, Napoli, Italy
7Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”, Naples, Italy
8Pathology Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, Naples, Italy
9Pharmacy Unit, Istituto Nazionale Tumori, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy
10Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’, IRCCS, Napoli, Italy
11Psicology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’, IRCCS, Napoli, Italy
12Division of Urology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori ‘Fondazione G. Pascale’, IRCCS, Naples, Italy
13Scientific Directorate, Istituto Nazionale Tumori ‘Fondazione G. Pascale’, IRCCS, Naples, Italy
*These authors have contributed equally to this work
Correspondence to:
Michele Caraglia, email: [email protected], [email protected]
Keywords: microRNAs, prostate cancer, biomarkers, oncogenic miRNAs, tumor suppressor miRNAs
Received: February 06, 2017 Accepted: March 25, 2017 Published: April 07, 2017
ABSTRACT
Prostate cancer is the second highest cause of cancer mortality after lung tumours. In USA it affects about 2.8 million men and the incidence increases with age in many countries. Therefore, early diagnosis is a very important step for patient clinical evaluation and for a selective and efficient therapy. The study of miRNAs’ functions and molecular mechanisms has brought new knowledge in biological processes of cancer. In prostate cancer there is a deregulation of several miRNAs that may function as tumour suppressors or oncogenes. The aim of this review is to analyze the progress made to our understanding of the role of miRNA dysregulation in prostate cancer tumourigenesis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16933